Astellas Pharma Inc. (OTCMKTS:ALPMY) Short Interest Update

Astellas Pharma Inc. (OTCMKTS:ALPMYGet Rating) was the recipient of a large decline in short interest during the month of May. As of May 15th, there was short interest totalling 22,400 shares, a decline of 62.5% from the April 30th total of 59,700 shares. Based on an average daily trading volume, of 339,300 shares, the short-interest ratio is currently 0.1 days.

A number of research firms have commented on ALPMY. Jefferies Financial Group lowered Astellas Pharma from a “buy” rating to a “hold” rating in a research report on Wednesday, February 23rd. Zacks Investment Research lowered Astellas Pharma from a “buy” rating to a “hold” rating in a research report on Monday, May 9th. Finally, Citigroup began coverage on Astellas Pharma in a research report on Tuesday, April 12th. They issued a “buy” rating on the stock.

Shares of Astellas Pharma stock opened at $15.67 on Thursday. Astellas Pharma has a one year low of $14.21 and a one year high of $18.46. The stock’s 50-day moving average is $15.64 and its 200 day moving average is $16.19. The firm has a market cap of $28.77 billion, a price-to-earnings ratio of 26.12, a PEG ratio of 0.59 and a beta of 0.57.

About Astellas Pharma (Get Rating)

Astellas Pharma Inc engages in the manufacture, marketing, import, and export of pharmaceuticals worldwide. It provides XTANDI, an androgen receptor signaling inhibitor for prostate cancer; XOSPATA, a FLT3 inhibitor for adult patients with relapsed or refractory acute myeloid leukemia with a FLT3 mutation-positive; PADCEV, a treatment solution for adult patients with locally advanced or metastatic urothelial cancer; Betanis/Myrbetriq/BETMIGA, a beta-3 adrenergic receptor agonist for the treatment of urgency, urinary frequency, and urge urinary incontinence; Evrenzo, an oral treatment for anemia associated with chronic kidney disease; and Prograf and Advagraf/Graceptor/ASTAGRAF, which are immunosuppressants used to suppress organ rejection following a transplant.

Featured Articles

Want More Great Investing Ideas?

Receive News & Ratings for Astellas Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Astellas Pharma and related companies with's FREE daily email newsletter.